BASEL, Switzerland, CAMBRIDGE, Mass., and GAITHERSBURG, Md., March 14, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative ...
Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available ...
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing ...
SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a biotechnology start-up based in San Diego, is pleased to announce a major stride in its ongoing Series A funding round. Known for their CRISPR Analytics ...
SAN DIEGO--(BUSINESS WIRE)--On January 9 th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of ...
Barchart on MSN
This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?
The global cell therapy market was valued at $5.88 billion in 2024 and is on track to hit $44.39 billion by 2034, expanding ...
CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...
* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments * Says commercial license builds on an existing research and ...
Investor's Business Daily on MSN
Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged
Crispr stock reversed lower Monday, while Intellia stock surged, on promising updates for their gene-editing efforts.
This biotech has already made impressive contributions to medicine, and it could make more. But does that make it a buy?
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback